Femtech World reports the rise was steepest among new mothers with type 2 diabetes, a group seeing more GLP-1 use after giving birth.
Recap by typeshit. Post by @femtechworld on Instagram.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
A Facebook roundup lines up CagriSema's REIMAGINE 2 numbers, with time in range rising from 52.3% to 88.0% by week 68, next to retatrutide's TRIUMPH-2 results.
The Wall Street Journal reports black-market producers are pitching Americans substances for tanning, tissue repair and weight loss.
Loading…